The barber's chairman

Ebb & Flow

The barber's chairman

Meanwhile,Anthra cited market conditions for withdrawing its NASDAQ IPO. The company is starting to generate royalty revenue, as partner Medeva launched Anthra's Valstar valrubicin in the U.S. in February to treat carcinoma in situ of the bladder. Anthra originally filed in March 1998 to sell 2.4 million shares at $9.50-$11.50, and then upped the deal to 2.7 million shares last May.


Read the full 681 word article

How to gain access

Continue reading with a
two-week free trial.